Evaluation of Efficacy and Safety of Clevira as an Add on Drug in Mild to Moderate COVID-19 Positive Patients: A Randomised Control Trial
| Autor: | R Narayanababu, S Ramesh Kannan, R Lenin, M Sakthibalan, KM Sudha, K Gowtham, Arther Paul, Esekia David |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Journal of Clinical and Diagnostic Research, Vol 16, Iss 2, Pp KC01-KC07 (2022) |
| Druh dokumentu: | article |
| ISSN: | 2249-782X 0973-709X |
| DOI: | 10.7860/JCDR/2022/51996.15940 |
| Popis: | Introduction: Coronavirus Disease-2019 (COVID-19) has caused a devastating pandemic. Despite the worldwide efforts to find a therapeutic strategy and prophylaxis, we have not attained a complete success. Hence, there exists an urgent need for development of alternative solutions from Ayurveda system of medicine for COVID-19. Aim: To evaluate clevira, a polyherbal ayurvedic formulation, for its efficacy and safety in treatment of mild to moderate COVID-19 patients as an add on drug. Materials and Methods: This randomised control trial was carried out from May 2020 to July 2020, in 100 patients (50 in test group and 50 in control group) confirmed with COVID-19 infection (mild to moderate cases) by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) at a tertiary care Government Medical College and Hospital in Chennai, India. The test group received tablet clevira orally twice daily after food, in the morning and night for 14 days, as an add on, in addition to standard care of treatment as received by the control group. The primary outcome was assessment of clinical recovery, proportion of patients with swabs negative for COVID-19 in RT-PCR and reduction of viral cycle threshold ratio. The results of the both group were analysed and compared using Chi-square test and Student’s t-test. Results: Total 100 patients were enrolled for the study, mean age of test group was 36.64 and control group was 31.08. Significant improvement (p-value=0.0338) was seen in patients on day 5, who got treated with clevira as add on drug. An 43 (86%) of patients turned out to be COVID-19 RT-PCR test negative on day 5 while in the control group 33 (66%) of patients turned out to be negative. There was a statistically significant difference (p-value=0.0196) between the test and control groups on comparing the mean difference in CT value results between day 1 and day 5. Clevira when given in addition to the standard of care, showed a significant improvement in signs and symptoms of COVID-19 infection. Conclusion: Clevira, with its polyherbal ingredients showed a significant antiviral action against coronavirus when given in addition to the standard of care medications suggested by Indian Council of Medical Research (ICMR), over a period of 14 days in treatment of mild to moderate COVID-19 patients. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|